Literature DB >> 2365065

Antithrombin Rouen-IV 24 Arg----Cys. The amino-terminal contribution to heparin binding.

J Y Borg1, S O Brennan, R W Carrell, P George, D J Perry, J Shaw.   

Abstract

A variant antithrombin with reduced heparin affinity was shown by mass spectrometry sequencing and DNA amplification to have a substitution of a cysteine for an arginine at residue 24. The position of Arg-24 can be fixed within a 12 A radius from the bridge at Cys-21. This is compatible with findings in the homologous protease nexin-1 which indicate an extension of the binding site of heparin from the D-helix to under the adjacent amino-terminal pole.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2365065     DOI: 10.1016/0014-5793(90)81530-2

Source DB:  PubMed          Journal:  FEBS Lett        ISSN: 0014-5793            Impact factor:   4.124


  5 in total

1.  Pleiotropic effects of antithrombin strand 1C substitution mutations.

Authors:  D A Lane; R J Olds; J Conard; M Boisclair; S C Bock; M Hultin; U Abildgaard; H Ireland; E Thompson; G Sas
Journal:  J Clin Invest       Date:  1992-12       Impact factor: 14.808

2.  The N-terminal segment of antithrombin acts as a steric gate for the binding of heparin.

Authors:  H L Fitton; R Skinner; T R Dafforn; L Jin; R N Pike
Journal:  Protein Sci       Date:  1998-03       Impact factor: 6.725

Review 3.  Glycosaminoglycans and the regulation of blood coagulation.

Authors:  M C Bourin; U Lindahl
Journal:  Biochem J       Date:  1993-01-15       Impact factor: 3.857

4.  Five novel and four recurrent point mutations in the antithrombin gene causing venous thrombosis.

Authors:  Keiko Nagaizumi; Hiroshi Inaba; Kagehiro Amano; Midori Suzuki; Morio Arai; Katsuyuki Fukutake
Journal:  Int J Hematol       Date:  2003-07       Impact factor: 2.490

5.  Antithrombin III deficiency in Indian patients with deep vein thrombosis: identification of first India based AT variants including a novel point mutation (T280A) that leads to aggregation.

Authors:  Teena Bhakuni; Amit Sharma; Qudsia Rashid; Charu Kapil; Renu Saxena; Manoranjan Mahapatra; Mohamad Aman Jairajpuri
Journal:  PLoS One       Date:  2015-03-26       Impact factor: 3.240

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.